ASND (US) share price forecast & AI signal — Ascendis Pharma A/S
Week of 2026-10-30 · Healthcare
Exact confidence, 1-week / 1-month / 3-month breakdown, plain-English AI write-up, bull-vs-bear debate, support & resistance.
Get 5 free tokens — no card Already a member? Open the full analysisWhat the model sees in ASND
Ascendis Pharma A/S is a Healthcare stock listed on the US. For the week of 2026-10-30 the ACE machine-learning model rates it a SELL with low confidence, based on technical indicators and the stock's own historical patterns across three time horizons. The direction is updated every model run.
About Ascendis Pharma A/S
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Recent closes
| Date | Close |
|---|---|
| 2026-11-06 | $256.82 |
| 2026-11-05 | $253.45 |
| 2026-11-04 | $257.93 |
| 2026-11-03 | $250.17 |
| 2026-11-02 | $248.98 |
| 2026-10-30 | $251.27 |
| 2026-10-29 | $253.00 |
ASND FAQ
Is Ascendis Pharma A/S (ASND) a buy or sell this week?
The ACE Stock Bots machine-learning model rates ASND a SELL for the week of 2026-10-30 with low confidence. The exact confidence and the 1-week, 1-month and 3-month breakdown are free with a signup (5 analysis tokens, no card).
What is the AI share price forecast for ASND?
Every week the model scores ASND across three horizons using technical indicators and the stock's own historical patterns. An AI then writes a plain-English summary with support and resistance levels, and a bull analyst and a bear analyst argue the case.
Is this financial advice?
No. ACE Stock Bots provides general information generated by software. It does not consider your objectives, financial situation or needs. Read the disclaimer and consider licensed advice before acting.
Other Healthcare stocks on the US
This week's top US picks · All US stocks
Signals are generated by software for general information only and are not a recommendation to buy or sell. See the disclaimer.